Dr. Philip Mease is the past president and founding organizer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), an international organization of over 1,000 rheumatology and dermatology researchers dedicated to research and education about psoriasis and psoriatic arthritis. Dr. Mease received his undergraduate and medical degrees from Stanford University. He completed his internal medicine residency and rheumatology fellowship at the University of Washington. He cares for patients, directs the rheumatology research division at Swedish Medical Center, and is a Clinical Professor of Medicine at the University of Washington in Seattle.

Dr. Mease’s research interests have included psoriatic arthritis (PsA) and spondyloarthritis (SpA), rheumatoid arthritis (RA), fibromyalgia (FM,) and osteoporosis. His work includes research on disease state, developing outcome measures, and determining the efficacy and safety of emerging therapies for these conditions. His seminal 2000 Lancet paper established the efficacy of anti-tumor necrosis factor therapy in PsA. He has authored over 350 journal articles, numerous abstracts, and book chapters. He is a prolific international speaker at academic congresses, grand rounds, and other educational activities for rheumatologists and dermatologists. He is considered a global key opinion leader, researcher, educator, and clinician regarding SpA, including ankylosing spondylitis (AS), non-radiographic spondyloarthritis (nr-axSpA), and psoriatic arthritis. He reviews Arthritis & Rheumatology, Arthritis Care & Research, Annals of the Rheumatic Diseases, The Journal of Rheumatology, Seminars in Arthritis and Rheumatism, and other rheumatology journals.